Carolina Landeen, MD

Department

• Medicine

Position

• Assistant Professor

Articles

• , 30
• , 160, A2062
• , 160, A1069
• , 11;8, 3270-3275

Publications

• , 162, A1737

Presentations

Grant Funding Received

• Department of Pulmonary/Critical Care. Creighton University Medical Center. Industry-sponsored, multicenter trial. TR701-132: A Phase 3 Randomized Double-Blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia. Sub-investigator. 2016 -2019
• Department of Pulmonary/Critical Care. Creighton University Medical Center Industry-sponsored, multicenter trial. IRC-005: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A. Sub-investigator. 2016 - 2019.
• Department of Pulmonary/Critical Care. Creighton University Medical Center. Industry-sponsored, multicenter trial. CF-301: A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF 301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients with Staphylococcus aureus Bloodstream Infections (Bacteremia) Including Right Sided Endocarditis. Sub-investigator. 2017 - 2019.
• Industry-sponsored, multicenter trial. BI-1199.247: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). Sub-investigator. 2017- 2019.
• Industry-sponsored, multicenter trial. CXA-NP-11-04: A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study To Assess The Safety And Efficacy Of Intravenous Ceftolozane/Tazobactam Compared With Meropenem In Adult Patients With Ventilated Nosocomial Pneumonia. Sub-investigator. 2017 - 2019.
• Industry-sponsored, multicenter trial. Melinta: A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study To Evaluate The Safety And Efficacy Of Intravenous To Oral Delafloxacin In Adult Subjects With Community-Acquired Bacterial Pneumonia. Sub-investigator. 2017 - 2019
• Industry-sponsored, multicenter trial. Takeda: A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance. Sub-investigator. 2017 -2019.